Related Issuers
by Stephen Carter
Mar 28, 2024 10:03 AM ET
Neopharmed Gentili SpA (NEGENT) EUR750m144A/Reg S fixed/floating sr sec notes 2-part. B3/B/B+ (stable/sable/stable). Via BNP (B&D)/GS jt physical books/IMI jt glocos/Banca Akros/CA/JPM/Natixis jt books. No reg rights. List Lux. NY law. Settles 04/08.
- EUR400m (from expect EUR375m, and EUR300m minimum) sr sec FRN due 2030 (6y). NC1 (MWC B+50bp), then at 101, par. IPT: E+450bp, 0%, 99.00-99.50. Px talk: E+425-450bp, 0%, 99.50. Final terms: EUR400m at E+425bp, 0% floor, at 99.50.
- EUR350m (from expected EUR375m, and EUR300m minimum) sr sec fixed-rate notes due 2030 (6y). NC2 (MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Special call: 10% per year the first 2 years at 103. IPT: low-mid 7s. Px talk: 7.00%-7.25%. Final terms: EUR350m 7.125% at par.
Did investor call at 11am UKT 03/25, Q&A sessions 03/25-27. Books closed at 12pm UKT today. Reconfirms due 2:30pm UKT today. Pricing today UK afternoon. UOP: repay the existing EUR700m unitranche notes, and EUR26m for cash on the B/S. Equity sponsors: Ardian and NB Renaissance. Biz: a leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products. HQ: Milan, Italy.